A double-blind placebo-controlled study to evaluate valacyclovir alone and with aspirin for asymptomatic HSV-1 DNA shedding in human tears and saliva

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 12, 2009, Pages 5601-5608

  Kumar, Manish ^a   Hill, James M ^a,b   Clement, Christian ^a   Varnell, Emily D ^a   Thompson, Hilary W ^a,c   Kaufman, Herbert E ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; VALACICLOVIR; VIRUS DNA; ACICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; VALINE;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DETERMINATION; DOUBLE BLIND PROCEDURE; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; LACRIMAL FLUID; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALIVA; TREATMENT RESPONSE; VIRUS SHEDDING; AGED; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; GENE DOSAGE; ISOLATION AND PURIFICATION; MIDDLE AGED; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY;

ACYCLOVIR; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIVIRAL AGENTS; ASPIRIN; DNA, VIRAL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENE DOSAGE; HERPESVIRUS 1, HUMAN; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SALIVA; TEARS; VALINE; VIRUS SHEDDING; YOUNG ADULT;

EID: 73349088448     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3729     Document Type: Article

References (46)

1. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea. 2001;20(1):1-13.
2. Whitley RJ, Roizman B. Herpes simplex viruses. In: Richman DD, Whitley RJ, Hayden FG, eds. Clinical Virology. Washington, DC: ASM Press; 2009:409-436.
3. Kaufman HE, Rayfield MA, Gebhardt BM. Herpes simplex infections. In: Kaufman HE, Barron BA, McDonald MB, eds. The Cornea. Boston: Butterworth-Heinemann; 1998:247-277.
4. Roizman B, Knipe DM, Whitley RJ. Herpes simplex viruses. In: Knipe DM, Howley PM, eds. Fields Virology. 5th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2007:2503-2602.
5. Toma HS, Murina AT, Areaux RG Jr, et al. Ocular HSV-1 latency, reactivation and recurrent disease. Semin Ophthalmol. 2008; 23(4):249-273.
6. Sacks SL, Griffiths PD, Corey L, et al. HSV shedding. Antiviral Res. 2004;63(suppl 1):S19-S26.
7. Xu F, Lee FK, Morrow RA, et al. Seroprevalence of herpes simplex virus type 1 in children in the United States. J Pediatr. 2007; 151(4):374-377.
8. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964-973.
9. Kaufman HE, Azcuy AM, Varnell ED, Sloop GD, Thompson HW, Hill JM. HSV-1 DNA in tears and saliva of normal adults. Invest Ophthalmol Vis Sci. 2005;46(1):241-247.
10. Miller CS, Danaher RJ. Asymptomatic shedding of herpes simplex virus (HSV) in the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105(1):43-50.
11. Hyland PL, Coulter WA, Abu-Ruman I, et al. Asymptomatic shedding of HSV-1 in patients undergoing oral surgical procedures and attending for noninvasive treatment. Oral Dis. 2007;13(4):414-418.
12. Kaufman HE, Brown DC, Ellison EM. Recurrent herpes in the rabbit and man. Science. 1967;156(3782):1628-1629.
13. Abiko Y, Ikeda M, Hondo R. Secretion and dynamics of herpes simplex virus in tears and saliva of patients with Bell's palsy. Otol Neurotol. 2002;23(5):779-783.
14. Fukuda M, Deai T, Hibino T, Higaki S, Hayashi K, Shimomura Y. Quantitative analysis of herpes simplex virus genome in tears from patients with herpetic keratitis. Cornea. 2003;22(7 suppl):S55-S60.
15. Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis. 2008;198(8):1141-1149.
16. Hill JM, Ball MJ, Neumann DM, et al. The high prevalence of herpes simplex virus type 1 DNA in human trigeminal ganglia is not a function of age or gender. J Virol. 2008;82(16):8230-8234.
17. Kriesel JD, Pisani PL, McKeough MB, Baringer JR, Spruance SL. Correlation between detection of herpes simplex virus in oral secretions by PCR and susceptibility to experimental UV radiation-induced herpes labialis. J Clin Microbiol. 1994;32:3088-3090.
18. Arora A, Mendoza N, Brantley J, Yates B, Dix L, Tyring S. Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompro-mised patients 18 years of age and older. J Infect Dis. 2008;197(9): 1289-1295.
19. Bartlett BL, Tyring SK, Fife K, et al. Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: The RELIEF trial. J Clin Virol. 2008;43(2):190-195.
20. Bavaro JB, Drolette L, Koelle DM, et al. One-day regimen of vala-cyclovir for treatment of recurrent genital herpes simplex virus 2 infection. Sex Transm Dis. 2008;35(4):383-386.
21. Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis. 2004;190(8):1374-1381.
22. Kaufman HE, Varnell ED, Thompson HW. Cidofovir and experimental herpetic stromal disease. Arch Ophthalmol. 1999;117(7): 925-928.
23. Kaye SB, Madan N, Dowd TC, Hart CA, McCarthy K, Patterson A. Ocular shedding of herpes simplex virus. Br J Ophthalmol. 1990; 74(2):114-116.
24. Lazarus HM, Belanger R, Candoni A, Aoun M, Jurewicz R, Marks L. Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclo-vir-controlled trial. The Penciclovir Immunocompromised Study Group. Antimicrob Agents Chemother. 1999;43(5):1192-1197.
25. Loutsch JM, Sainz B Jr, Marquart ME, et al. Effect of famciclovir on herpes simplex virus type 1 corneal disease and establishment of latency in rabbits. Antimicrob Agents Chemother. 2001;45(7): 2044-2053.
26. Miller CS, Avdiushko SA, Kryscio RJ, Danaher RJ, Jacob RJ. Effect of prophylactic valacyclovir on the presence of human herpesvirus DNA in saliva of healthy individuals after dental treatment. J Clin Microbiol. 2005;43(5):2173-2180.
27. Miller CS, Cunningham LL, Lindroth JE, Avdiushko SA. The efficacy of valacyclovir in preventing recurrent herpes simplex virus infections associated with dental procedures. J Am Dent Assoc. 2004; 135(9):1311-1318.
28. Sperling RS, Fife KH, Warren TJ, Dix LP, Brennan CA. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes. Sex Transm Dis. 2008;35(3):286-290.
29. Yin MT, Brust JCM, Tieu HV, et al. Anti herpesvirus, anti-hepatitis virus, and antirespiratory virus agents. In: Richman DD, Whitley RJ, Hayden FG, eds. Clinical Virology. Washington, DC: ASM Press; 2009:409-436.
30. Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD Jr. Acyclovir suppression to prevent clinical recurrences at delivery after first episode genital herpes in pregnancy: an open-label trial. Infect Dis Obstet Gynecol. 2001;9(2):75-80.
31. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med. 1996;124:8-15:1996.
32. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004; 350(1):11-20.
33. Anand BS, Hill JM, Dey S, et al. In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model. Invest Oph-thalmol Vis Sci. 2003;44:2529-2534.
34. Majumdar S, Nashed YE, Patel K, et al. Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. J Ocul Pharmacol Ther. 2005;21(6):463-474.
35. Sanitato JJ, Asbell PA, Varnell ED, Kissling GE, Kaufman HE. Acy-clovir in the treatment of herpetic stromal disease. Am J Ophthal-mol. 1984;98(5):537-547.
36. Gebhardt BM, Varnell ED, Kaufman HE. Acetylsalicylic acid reduces viral shedding induced by thermal stress. Curr Eye Res. 2004;29(2-3):119-125.
37. Gebhardt BM, Varnell ED, Kaufman HE. Inhibition of cyclooxygen-ase 2 synthesis suppresses herpes simplex virus type 1 reactivation. J Ocul Pharmacol Ther. 2005;21(12):114-120.
38. Kaufman HE, Varnell ED, Thompson HW. Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic kerati-tis. Arch Ophthalmol. 1998;116(6):777-780.
39. Kameyama T, Sujaku C, Yamamoto S, Hwang CB, Shillitoe EJ. Shedding of herpes simplex virus type 1 into saliva. J Oral Pathol. 1988;17(9-10):478-481.
40. Mackay IM, Arden KE, Nitsche A. Real-time PCR in virology. Nucleic Acids Res. 2002;30(6):1292-1305.
41. Leigh JF, Acharya N, Cevallos V, Margolis TP. Does asymptomatic shedding of herpes simplex virus on the ocular surface lead to false-positive diagnostic PCR results? Br J Ophthalmol. 2008;92(3): 435-436.
42. Cole JWL, Gizzle JE. Applications of multivariate analysis of variance to repeated measurements. Exp Biometrics. 1966;22:810-828.
43. Wachsman M, Aurelian L, Burnett JW. The prophylactic use of cyclooxygenase inhibitors in recurrent herpes simplex infections. Br J Dermatol. 1990;123(3):375-380.
44. Karadi I, Karpati S, Romics L. Aspirin in the management of recurrent herpes simplex virus infection. Ann Internal Med. 1998; 128(8):696-697.
45. Robert PY, Adenis JP, Denis F, Alain S, Ranger-Rogez S. Herpes simplex virus DNA in corneal transplants: prospective study of 38 recipients. J Med Virol. 2003;71(1):69-74.
46. Malm G, Forsgren M. Neonatal herpes simplex virus infections: HSV DNA in cerebrospinal fluid and serum. Arch Dis Child Fetal Neonatal Ed. 1999;81(1):F24-F29.